Latest news and press releases about Aptorum Group Limited (APM): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases.
Price
| Price | $8.26 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.34 |
| EV / EBITDA | -4.28 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -5.90% |
| Return on Invested Capital | -10.36% |
| Return on Assets | -7.29% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADIL · ADXN · ARDS · ATHE · ATXI · OXBR · RKTO
Explore sector: Healthcare · Biotechnology
More sections of APM: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks